

Pharmaceutical Management Agency

Section H Update for Hospital Pharmaceuticals

Effective 1 August 2017



Contents

Summary of decisions effective 1 August 2017	3
Section H changes to Part II	6
Index	10

Summary of decisions

EFFECTIVE 1 AUGUST 2017

- Amoxicillin with clavulanic acid (Augmentin) tab 500 mg with clavulanic acid 125 mg – price decrease and addition of HSS
- Aztreonam (Azactam) inj 1 g vial – price increase
- Bisoprolol fumarate (Bosvate) tab 2.5 mg, 5 mg and 10 mg – price decrease
- Celecoxib (Celecoxib Pfizer) cap 100 mg and 200 mg – amended restriction
- Citrate sodium inj 4% (200 mg per 5 ml), 5 ml ampoule, inj 46.7% (2.36 g per 5 ml), 5 ml ampoule, and inj 46.7% (1.4 g per 3 ml), 3 ml syringe – amended chemical name and presentation
- Clarithromycin (Klacid) inj 500 mg vial – new listing
- Clarithromycin (Martindale) inj 500 mg vial – HSS delayed and price decrease
- Colecalciferol (Vit.D3) cap 1.25 mg (50,000 iu) – price decrease and addition of HSS
- Desmopressin acetate (Desmopressin-PH&T) nasal spray 10 mcg per dose – price increase and addition of HSS
- Dexamethasone phosphate (Max Health) inj 4 mg per ml, 2 ml ampoule, 5 inj pack – to be delisted 1 September 2017
- Emulsifying ointment (Jaychem) oint BP, 100 g – addition of HSS
- Emulsifying ointment (AFT) oint BP, 500 g – price increase and addition of HSS
- Etoricoxib tab 30 mg, 60 mg, 90 mg and 120 mg – amended restriction
- Fentanyl (Fentanyl Sandoz) patch 12.5 mcg per hour, 50 mcg per hour, 75 mcg per hour and 100 mcg per hour – price increase and addition of HSS
- Fentanyl (Fentanyl Sandoz) patch 25 mcg per hour – addition of HSS
- Glucose [dextrose] (Biomed) inj 50%, 10 ml ampoule – price increase and addition of HSS
- Glucose [dextrose] (Biomed) inj 50%, 90 ml bottle – addition of HSS
- Imatinib mesilate (Imatinib-AFT) cap 100 mg and 400 mg – price decrease and addition of HSS
- Ipratropium bromide (Univent) aqueous nasal spray 0.03% – price increase and addition of HSS
- Ispaghula (psyllium) husk (Konsyl-D) powder for oral soln – price increase and addition of HSS
- Isosorbide mononitrate (Ismo-20) tab 20 mg – price increase and addition of HSS
- Lidocaine [lignocaine] hydrochloride (Mucosoothe) oral (gel) soln 2% – new listing and addition of HSS

Summary of decisions – effective 1 August 2017 (continued)

- Lidocaine [lignocaine] hydrochloride (Xylocaine Viscous) oral (gel) soln 2% – to be delisted 1 October 2017
 - Morphine sulphate (Biomed) inj 1 mg per ml, 100 ml bag, 10 ml syringe and 50 ml syringe; 5 inj packs – pack size change and addition of HSS
 - Morphine sulphate (Biomed) inj 1 mg per ml, 100 ml bag, 10 ml syringe and 50 ml syringe; 10 inj packs – to be delisted 1 October 2017
 - Naproxen (Naprosyn SR 750 and Naprosyn SR 1000) tab long-acting 750 mg and 1 g, 90 tab pack – to be delisted 1 October 2017
 - Nicotinic acid (Apo-Nicotinic Acid) tab 50 mg and 500 mg – price increase and addition of HSS
 - Nystatin (Nilstat) oral liquid 100,000 u per ml – new listing and addition of HSS
 - Nystatin (m-Nystatin) oral liquid 100,000 u per ml – to be delisted 1 October 2017
 - Oestriol (Ovestin) crm 1 mg per g with applicator and pessaries 500 mcg – new listing and addition of HSS
 - Paclitaxel (Paclitaxel Ebewe) inj 6 mg per ml, 5 ml and 16.7 ml vial – price increase and addition of HSS
 - Paclitaxel (Paclitaxel Ebewe) inj 6 mg per ml, 50 ml vial – price decrease and addition of HSS
 - Pegylated interferon alfa-2a (Pegasys) inj 180 mcg prefilled syringe – price decrease and addition of HSS
 - Pegylated interferon alfa-2a (Pegasys RBV Combination Pack) inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) – delist delayed until further notice
 - Permethrin (A-Scabies) lotn 5% - price increase and addition of HSS
 - Pine tar with trolamine laurilsulfate and fluorescein (Pinetarsol) soln 2.3% with trolamine laurilsulfate and fluorescein sodium, 500 ml – price increase and addition of HSS
 - Pine tar with trolamine laurilsulfate and fluorescein (Pinetarsol) soln 2.3% with trolamine laurilsulfate and fluorescein sodium, 1,000 ml – to be delisted from 1 October 2017
 - Pyridoxine hydrochloride (Apo-Pyridoxine) tab 50 mg – price increase and addition of HSS
 - Ranitidine (Ranitidine Relief) tab 150 mg and 300 mg – price increase and addition of HSS
 - Ranitidine (Peptisoothe) oral liq 150 mg per 10 ml – price increase and addition of HSS
-

Summary of decisions – effective 1 August 2017 (continued)

- Remifentanyl (Remifentanyl-AFT) inj 1 mg and 2 mg vial – new listing, amended chemical name and addition of HSS
- Remifentanyl (Ultiva) inj 1 mg and 2 mg vial – to be delisted 1 October 2017
- Sulfadiazine silver (Flamazine) crm 1% - amended chemical name
- Trimethoprim with sulphamethoxazole [co-trimoxazole] (Deprim) oral liq 8 mg with sulphamethaxozole 40 mg per ml – price increase and addition of HSS

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 August 2017

ALIMENTARY TRACT AND METABOLISM

15	RANITIDINE (↑ price and addition of HSS)			
	Tab 150 mg – 1% DV Oct-17 to 2020	12.91	500	Ranitidine Relief
	Tab 300 mg – 1% DV Oct-17 to 2020	18.21	500	Ranitidine Relief
	Oral liq 150 mg per 10 ml – 1% DV Oct-17 to 2020	5.14	300 ml	Peptisoothe
19	ISPAGHULA (PSYLLIUM) HUSK (↑ price and addition of HSS)			
	Powder for oral soln – 1% DV Oct-17 to 2020	6.05	500 g	Konsyl-D
25	NYSTATIN (brand change)			
	Oral liquid 100,000 u per ml – 1% DV Oct-17 to 2020	1.95	24 ml	Nilstat
	Note – m-Nystatin oral liquid 100,000 u per ml to be delisted from 1 October 2017.			
27	PYRIDOXINE HYDROCHLORIDE (↑ price and addition of HSS)			
	Tab 50 mg – 1% DV Oct-17 to 2020	13.63	500	Apo-Pyridoxine
27	COLECALCIFEROL (↓ price and addition of HSS)			
	Cap 1.25 mg (50,000 iu) – 1% DV Oct-17 to 2020	2.50	12	Vit.D3

BLOOD AND BLOOD FORMING ORGANS

35	TRISODIUM CITRATE CITRATE SODIUM (amended chemical name and presentation)			
	Inj 4% (200 mg per 5 ml), 5 ml ampoule			
	Inj 46.7% (2.36 g per 5 ml), 5 ml ampoule			
	Inj 46.7% (1.4 g per 3 ml), 3 ml syringe			
38	GLUCOSE [DEXTROSE] (addition of HSS)			
	Inj 50%, 10 ml ampoule – 1% DV Oct-17 to 2020 (↑ price).....	29.50	5	Biomed
	Inj 50%, 90 ml bottle – 1% DV Oct-17 to 2020	14.50	1	Biomed

CARDIOVASCULAR SYSTEM

45	BISOPROLOL FUMARATE (↓ price)			
	Tab 2.5 mg	1.18	30	Bosvate
	Tab 5 mg	1.72	30	Bosvate
	Tab 10 mg	3.13	30	Bosvate
50	NICOTINIC ACID (↑ price and addition of HSS)			
	Tab 50 mg – 1% DV Oct-17 to 2020	4.12	100	Apo-Nicotinic Acid
	Tab 500 mg – 1% DV Oct-17 to 2020	17.89	100	Apo-Nicotinic Acid
50	ISOSORBIDE MONONITRATE (↑ price and addition of HSS)			
	Tab 20 mg – 1% DV Oct-17 to 2020	18.80	100	Ismo-20

➔ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2017 (continued)

DERMATOLOGICALS

55	SULPHADIAZINE SILVER SULFADIAZINE SILVER (amended chemical name) Crm 1% – 1% DV Aug-17 to 2020	10.80	50 g	Flamazine
56	PERMETHRIN († price and addition of HSS) Lotn 5% – 1% DV Oct-17 to 2020	3.69	30 ml	A-Scabies
57	EMULSIFYING OINTMENT (addition of HSS) Oint BP – 1% DV Oct-17 to 2020	1.84	100 g	Jaychem
	Note: DV limit applies to pack sizes of less than 200 g.			
	Oint BP, 500 g – 1% DV Oct-17 to 2020 († price).....	3.59	500 g	AFT
	Note: DV limit applies to pack sizes of greater than 200 g.			
59	PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCHEIN († price and addition of HSS) Soln 2.3% with trolamine laurilsulfate and fluorescein sodium – 1% DV Oct-17 to 2020	3.86	500 ml	Pinetarsol
	Note – Pinetarsol soln 2.3% with trolamine laurilsulfate and fluorescein, 1,000 ml pack to be delisted from 1 October 2017.			

GENITO-URINARY SYSTEM

63	OSTRIOL (new listing and addition of HSS) Crm 1 mg per g with applicator – 1% DV Oct-17 to 2020	6.62	15 g	Ovestin
	Pessaries 500 mcg – 1% DV Oct-17 to 2020	6.86	15	Ovestin

HORMONE PREPARATIONS

67	DEXAMETHASONE PHOSPHATE (delisting) Inj 4 mg per ml, 2 ml ampoule – 1% DV Jul-16 to 2019	12.59	5	Max Health
	Note – Max Health inj 4 mg per ml, 2 ml ampoule, 5 inj pack to be delisted from 1 September 2017. The 10 inj pack size remains listed.			
75	DESMOPRESSIN ACETATE († price and addition of HSS) Nasal spray 10 mcg per dose – 1% DV Oct-17 to 2020	23.95	6 ml	Desmopressin-PH&T

INFECTIONS

79	CLARITHROMYCIN (new listing) → Inj 500 mg vial.....	12.04	1	Klacid
79	CLARITHROMYCIN (HSS delayed and ↓ price) → Inj 500 mg vial – 1% DV Sep-17 to 2020	12.04	1	Martindale
80	AMOXICILLIN WITH CLAVULANIC ACID (↓ price and addition of HSS) Tab 500 mg with clavulanic acid 125 mg – 1% DV Oct-17 to 2020	1.88	20	Augmentin
82	AZTREONAM († price) → Inj 1 g vial.....	182.46	5	Azactam

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2017 (continued)

83	TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE] (↑ price and addition of HSS) Oral liq 8 mg with sulphamethoxazole 40 mg per ml – 1% DV Oct-17 to 2020	2.97	100 ml	Deprim
97	PEGYLATED INTERFERON ALFA-2A (↓ price and addition of HSS) → Inj 180 mcg prefilled syringe – 1% DV Oct-17 to 2020	500.00	4	Pegasys
97	PEGYLATED INTERFERON ALFA-2A (delisting delayed) → Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112).....	1,159.84	1	Pegasys RBV Combination Pack

Note – Pegasys RBV Combination Pack inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) delist delayed until further notice.

MUSCULOSKELETAL SYSTEM

107	CELECOXIB (amended restriction) Note – The DV limit of 1% applies to the celecoxib chemical rather than each individual line item. Cap 100 mg – 1% DV Aug-17 to 2020	3.63	60	Celecoxib Pfizer
	Cap 200 mg – 1% DV Aug-17 to 2020	2.30	30	Celecoxib Pfizer
	Restricted Initiation For preoperative and/or postoperative use for a total of up to 8 days' use.			
107	ETORICOXIB (amended restriction) → Tab 30 mg → Tab 60 mg → Tab 90 mg → Tab 120 mg			
	Restricted Initiation For preoperative and/or postoperative use for a total of up to 8 days' use. For in-vivo investigation of allergy only.			
108	NAPROXEN (delisting) Tab long-acting 750 mg – 1% DV Jun-15 to 2018	18.00	90	Naprosyn SR 750
	Tab long-acting 1 g – 1% DV Jun-15 to 2018	21.00	90	Naprosyn SR 1000
	Note – Naprosyn SR 750 tab long-acting 750 mg and Naprosyn SR 1000 tab long-acting 1 g, 90 tab pack to be delisted from 1 October 2017. The 28 tab pack remains listed.			

NERVOUS SYSTEM

112	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (brand change and amended presentation description) Oral (viscous gel) soln 2% – 1% DV Oct-17 to 2020	38.00	200 ml	Mucosoothe
	Note – Xylocaine Viscous oral (gel) soln 2% to be delisted from 1 October 2017.			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

Changes to Section H Part II – effective 1 August 2017 (continued)

114	FENTANYL (addition of HSS)			
	Patch 12.5 mcg per hour – 1% DV Oct-17 to 2020 (↑ price).....	2.95	5	Fentanyl Sandoz
	Patch 25 mcg per hour – 1% DV Oct-17 to 2020.....	3.66	5	Fentanyl Sandoz
	Patch 50 mcg per hour – 1% DV Oct-17 to 2020 (↑ price).....	6.65	5	Fentanyl Sandoz
	Patch 75 mcg per hour – 1% DV Oct-17 to 2020 (↑ price).....	9.25	5	Fentanyl Sandoz
	Patch 100 mcg per hour – 1% DV Oct-17 to 2020 (↑ price).....	11.40	5	Fentanyl Sandoz
115	MORPHINE SULPHATE (pack size change and addition of HSS)			
	Inj 1 mg per ml, 100 ml bag – 1% DV Oct-17 to 2020.....	97.25	5	Biomed
	Inj 1 mg per ml, 10 ml syringe – 1% DV Oct-17 to 2020.....	24.00	5	Biomed
	Inj 1 mg per ml, 50 ml syringe – 1% DV Oct-17 to 2020.....	50.75	5	Biomed
	Note – Biomed inj 1 mg per ml, 100 ml bag, 1 mg per ml, 10 ml syringe and 1 mg per ml, 50 ml syringe, 10 inj pack to be delisted from 1 October 2017.			
116	REMIFENTANIL HYDROCHLORIDE (brand change and amended chemical name)			
	Inj 1 mg vial – 1% DV Oct-17 to 2020.....	13.95	5	Remifentanil-AFT
	Inj 2 mg vial – 1% DV Oct-17 to 2020.....	19.95	5	Remifentanil-AFT
	Note – Ultiva inj 1 mg and 2 mg vial to be delisted from 1 October 2017.			

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

144	IMATINIB MESILATE (↓ price and addition of HSS)			
	Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule			
	Cap 100 mg – 1% DV Oct-17 to 2020.....	98.00	60	Imatinib-AFT
	Cap 400 mg – 1% DV Oct-17 to 2020.....	197.50	30	Imatinib-AFT
147	PACLITAXEL (↑ price and addition of HSS)			
	Inj 6 mg per ml, 5 ml vial – 1% DV Oct-17 to 2020.....	47.30	5	Paclitaxel Ebewe
	Inj 6 mg per ml, 16.7 ml vial – 1% DV Oct-17 to 2020.....	20.00	1	Paclitaxel Ebewe
147	PACLITAXEL (↓ price and addition of HSS)			
	Inj 6 mg per ml, 50 ml vial – 1% DV Oct-17 to 2020.....	35.35	1	Paclitaxel Ebewe

RESPIRATORY SYSTEM AND ALLERGIES

190	IPRATROPIUM BROMIDE (↑ price and addition of HSS)			
	Aqueous nasal spray 0.03% – 1% DV Oct-17 to 2020.....	4.61	15 ml	Univent

Effective 1 July 2017

NERVOUS SYSTEM

116	MORPHINE SULPHATE (Pharmacode change)			
	Tab immediate-release 10 mg – 1% DV Sep-17 to 2020.....	2.80	10	Sevredol
	Tab immediate-release 20 mg – 1% DV Sep-17 to 2020.....	5.52	10	Sevredol
	Note – this is a change from a bottle to blister pack (2520990 and 2521008 respectively). The bottle packs are to be delisted 1 October 2017.			

Index

Pharmaceuticals and brands

A		
Amoxicillin with clavulanic acid	7	
Apo-Nicotinic Acid	6	
Apo-Pyridoxine	6	
A-Scabies	7	
Augmentin	7	
Azactam	7	
Aztreonam	7	
B		
Bisoprolol fumarate	6	
Bosvate	6	
C		
Celecoxib	8	
Celecoxib Pfizer	8	
Citrate sodium	6	
Clarithromycin	7	
Colecalciferol	6	
Co-trimoxazole	8	
D		
Deprim	8	
Desmopressin acetate	7	
Desmopressin-PH&T	7	
Dexamethasone phosphate	7	
Dextrose	6	
E		
Emulsifying ointment	7	
Etoricoxib	8	
F		
Fentanyl	9	
Fentanyl Sandoz	9	
Flamazine	7	
G		
Glucose [dextrose]	6	
I		
Imatinib-AFT	9	
Imatinib mesilate	9	
Ipratropium bromide	9	
Ismo-20	6	
Isosorbide mononitrate	6	
Ispaghula (psyllium) husk	6	
K		
Klacid	7	
Konsyl-D	6	
L		
Lidocaine [lignocaine] hydrochloride	8	
Lignocaine	8	
M		
Morphine sulphate	9	
Mucosoothe	8	
N		
Naprosyn SR 750	8	
Naprosyn SR 1000	8	
Naproxen	8	
Nicotinic acid	6	
Nilstat	6	
Nystatin	6	
O		
Oestriol	7	
Ovestin	7	
P		
Paclitaxel	9	
Paclitaxel Ebewe	9	
Pegasys	8	
Pegasys RBV Combination Pack	8	
Pegylated interferon alfa-2A	8	
Peptisoothe	6	
Permethrin	7	
Pinetarsol	7	
Pine tar with trolamine laurilsulfate and fluorescein ..	7	
Pyridoxine hydrochloride	6	
R		
Ranitidine	6	
Ranitidine Relief	6	
Remifentanil	9	
Remifentanil-AFT	9	
Remifentanil hydrochloride	9	
S		
Sevredol	9	
Sulfadiazine silver	7	
Sulphadiazine silver	7	
T		
Trimethoprim with sulphamethoxazole [co-trimoxazole]	8	
Trisodium citrate	6	
U		
Univent	9	
V		
Vit.D3	6	



Email: enquiry@pharmac.govt.nz

www.pharmac.govt.nz/medicines/hospital-pharmaceuticals

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

ISSN 1179-3694 (Print) - ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.